PT  - JOURNAL ARTICLE
AU  - Azzam, Ahmed Y.
AU  - Essibayi, Muhammed Amir
AU  - Vaishnav, Dhrumil
AU  - Morsy, Mahmoud M.
AU  - Elamin, Osman
AU  - Al Zomia, Ahmed Saad
AU  - Alotaibi, Hammam A.
AU  - Alamoud, Ahmed
AU  - Mohamed, Adham A.
AU  - Ahmed, Omar S.
AU  - Elswedy, Adam
AU  - Abukhadijah, Hana J.
AU  - Atallah, Oday
AU  - Dmytriw, Adam A.
AU  - Altschul, David J.
TI  - Cardiometabolic Outcomes in Idiopathic Intracranial Hypertension: An International Matched-Cohort Study
AID  - 10.1101/2024.11.12.24317203
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.12.24317203
4099  - http://medrxiv.org/content/early/2024/11/13/2024.11.12.24317203.short
4100  - http://medrxiv.org/content/early/2024/11/13/2024.11.12.24317203.full
AB  - Introduction Idiopathic intracranial hypertension (IIH) has been traditionally viewed as a neuro-ophthalmic disorder, yet emerging evidence suggests broader systemic implications. Our study investigates the cardiometabolic outcomes associated with IIH through a comprehensive matched-cohort analysis.Methods We conducted a retrospective analysis of electronic health records from 2009 to 2024. We compared IIH patients with matched controls using propensity score matching based on age, sex, race, ethnicity, and baseline BMI. Cardiovascular and metabolic outcomes were assessed over a ten-year follow-up period, with additional stratified analyses comparing obese and non-obese subgroups.Results IIH patients demonstrated significantly increased risks of ischemic stroke/TIA (RR 2.515, 95% CI 2.250-2.812) and non-traumatic hemorrhagic stroke (RR 7.744, 95% CI 6.118-9.801). Notable metabolic findings included elevated risks of insulin resistance (RR 1.470, 95% CI 1.258-1.717) and type 2 diabetes mellitus (RR 1.210, 95% CI 1.171-1.250). These associations persisted in non-obese IIH patients, suggesting pathogenic mechanisms independent of adiposity. Additionally, IIH patients showed increased prevalence of polycystic ovarian syndrome (RR 1.470, 95% CI 1.258-1.717) and metabolic syndrome (RR 1.125, 95% CI 1.045-1.205).Conclusions Our findings highlight IIH as a complex multisystem disorder with significant cardiometabolic implications beyond its traditional neuro-ophthalmic presentation. The findings suggest the need for comprehensive cardiovascular and metabolic screening in IIH patients, regardless of BMI status, and indicate potential novel therapeutic targets for investigation.Competing Interest StatementThe project described was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through CTSA award number: UM1TR004400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Funding StatementThe project described was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through CTSA award number: UM1TR004400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All used data is available within TriNetX database platform.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes